Utilizing Protein-Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19

Area of Science:

• Immunology
• Biotechnology
• Infectious Diseases

Background:

• The COVID-19 pandemic necessitates improved diagnostic tools beyond traditional PCR and serological assays.
• Existing methods face limitations in sensitivity, specificity, and timely results for disease tracking.
• Dynamic monitoring of patient antibody profiles is crucial for understanding disease progression.

Purpose of the Study:

• To evaluate the efficacy of protein-peptide hybrid microarray (PPHM) technology for monitoring antibody dynamics in COVID-19 patients.
• To assess the potential of PPHM in predicting disease severity, progression, and patient prognosis.
• To identify specific antibody markers indicative of recovery status.

Main Methods:

• Utilized PPHM technology on serum samples from a discovery cohort of 20 COVID-19 patients.
• Tracked dynamic changes in serum antibodies over time.
• Analyzed data to correlate antibody profiles with disease severity and patient outcomes.

Main Results:

• PPHM technology demonstrated high effectiveness in detecting dynamic antibody changes in COVID-19 patients.
• Identified four specific polypeptide antibodies crucial for reflecting recovery status.
• Successfully predicted disease progression and patient prognosis based on antibody profiles.

Conclusions:

• PPHM technology offers a powerful approach for tracking antibody dynamics in COVID-19.
• Specific polypeptide antibodies identified by PPHM can serve as reliable indicators of prognosis.
• This technology holds potential for enhancing COVID-19 diagnosis and patient management.